Cargando…

Use of PD‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report

Pulmonary sarcomatoid carcinoma (PSC), characterized by poor differentiation, aggressive progression, and early metastasis, is a rare type of non‐small cell lung carcinoma (NSCLC), which shows a low response rate to conventional antitumor therapies and has a poor prognosis. With the achievements in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Li, Tao, Ning‐ning, Liang, Bin, Li, Dao‐wei, Li, Huai‐chen, Su, Li‐li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807335/ https://www.ncbi.nlm.nih.gov/pubmed/34953097 http://dx.doi.org/10.1111/1759-7714.14290

Ejemplares similares

Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report
por: Li, Yu-Feng, et al.
Publicado: (2022)

A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy
por: Cai, Ruoxue, et al.
Publicado: (2023)

Immunophenotyping of pulmonary sarcomatoid carcinoma
por: Ma, Yu, et al.
Publicado: (2022)

Perforated sarcomatoid carcinoma of the jejunum: Case report
por: HAN, NING, et al.
Publicado: (2013)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
por: Zhu, Shibin, et al.
Publicado: (2022)

Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma
por: Takeda, Kazuya, et al.
Publicado: (2016)

MET alterations in advanced pulmonary sarcomatoid carcinoma
por: Gong, Chen, et al.
Publicado: (2022)

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023)

Pulmonary sarcomatoid carcinoma mimicking pleural mesothelioma: A case report
por: Wang, Le, et al.
Publicado: (2021)

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations
por: Li, Xin, et al.
Publicado: (2020)

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases
por: Li, Teng, et al.
Publicado: (2023)

Pulmonary sarcomatoid carcinoma: a case report
por: Shen, Xiao-yong, et al.
Publicado: (2013)

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
por: Ye, Dingwei, et al.
Publicado: (2020)

Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report
por: Zhang, Yanqi, et al.
Publicado: (2023)

Surgery after combination therapy with a tyrosine kinase inhibitor and anti-PD-1 antibody in sarcomatoid hepatocellular carcinoma: case report and literature review
por: Liang, Bin, et al.
Publicado: (2023)

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage
por: Hong, Yuan, et al.
Publicado: (2021)

Recurrence of pulmonary sarcomatoid carcinoma presenting as haemothorax: a case report
por: Su, Chen, et al.
Publicado: (2023)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
por: Wu, Ming-Jun, et al.
Publicado: (2023)

Carcinosarcoma and sarcomatoid carcinoma of the stomach: Two case reports
por: Li, Youpeng, et al.
Publicado: (2021)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
por: Budha, Nageshwar, et al.
Publicado: (2022)

Pulmonary sarcomatoid carcinoma: Future prospects of adjuvant immunotherapy in advanced management
por: Agrawal, Anand
Publicado: (2020)

Chemotherapy for advanced pulmonary sarcomatoid carcinoma: a population-based propensity score matching study
por: Wang, Feng, et al.
Publicado: (2023)

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
por: Desai, Jayesh, et al.
Publicado: (2023)

Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report
por: Sun, Wei, et al.
Publicado: (2023)

A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
por: Sawatari, Kosuke, et al.
Publicado: (2022)

Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma
por: Sun, Jiachun, et al.
Publicado: (2022)

Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report
por: Qu, Fanjie, et al.
Publicado: (2021)

Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
por: Wen, Yingmei, et al.
Publicado: (2023)

Sarcomatoid carcinoma of the pancreas: A case report
por: Zhou, Dong-Kai, et al.
Publicado: (2019)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

Clinical, pathological and treatment factors associated with the survival of patients with pulmonary sarcomatoid carcinoma
por: Liang, Xiaohong, et al.
Publicado: (2020)

Gingival metastasis of a mediastinal pulmonary sarcomatoid carcinoma: a case report
por: Qin, Zhonghua, et al.
Publicado: (2019)

Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review
por: Piao, Mei-Na, et al.
Publicado: (2022)

Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma
por: Liang, Ziwei, et al.
Publicado: (2022)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
por: Taniguchi, Hirokazu, et al.
Publicado: (2021)

Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database
por: Chen, Mingjing, et al.
Publicado: (2021)

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience
por: Karim, Nagla Abdel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c73o0djoll0o10hp8u6r8kn1h0